Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease

Xinyue Lian(Renji Hospital), Jing Zou(Renji Hospital), Qiang Guo(Renji Hospital), Sheng Chen(Renji Hospital), Liangjing Lu(Renji Hospital), Ran Wang(Renji Hospital), Mengmeng Zhou(Renji Hospital), Qiong Fu(Renji Hospital), Yan Ye(Renji Hospital), Chunde Bao(Renji Hospital)
CHEST Journal
May 16, 2020
10.1016/j.chest.2020.04.057
Cited by 131Open Access
Full Text

Abstract

Related Papers

What do we mean by validating a prognostic model?
Douglas G. Altman, Patrick Royston|Statistics in Medicine|2000|1.4k
Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis
Shinji Sato, Michito Hirakata, Masataka Kuwana et al.|Arthritis & Rheumatism|2005|740
Interstitial lung disease in polymyositis and dermatomyositis
I. Marie, É. Hachulla, P. Chérìn et al.|Arthritis Care & Research|2002|486
Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?
Richard D. Sontheimer|Journal of the American Academy of Dermatology|2002|481
Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
Takahisa Gono, Shoichiro Sato, Yasushi Kawaguchi et al.|Lara D. Veeken|2012|337